What is an H2 Blocker?
H2 blockers (H2-receptor antagonists or H2RAs) are medications that decrease gastric acid secretion by blocking histamine-2 receptors on the parietal cells of the stomach, reducing both basal and stimulated acid production. 1
Mechanism of Action
H2RAs work by competitively inhibiting the histamine-2 receptor on gastric parietal cells, which is one of three pathways that stimulate acid secretion 1, 2. This blockade prevents histamine from triggering the cascade that leads to acid production. The acid-inhibiting effect begins within 30 minutes of administration, reaches peak plasma concentrations at 2.5 hours, and lasts approximately 6 hours 1.
Common H2 Blockers
The main H2RAs available include:
- Cimetidine (30-40 mg/kg/day in children)
- Ranitidine (5-10 mg/kg/day in children)
- Famotidine (1 mg/kg/day in children; most potent, 20-50 times more potent than cimetidine)
- Nizatidine (10 mg/kg/day in children)
Famotidine is the most potent H2RA currently available, being approximately 8 times more potent than ranitidine and 40 times more potent than cimetidine on a weight basis 3, 4.
Clinical Uses
H2 blockers are primarily used for:
- Gastroesophageal reflux disease (GERD) - particularly mild to moderate cases 1, 5
- Peptic ulcer disease - though now largely replaced by PPI therapy and H. pylori eradication 5, 6
- Prevention of NSAID-related ulcers - standard doses prevent duodenal ulcers but not gastric ulcers; double doses may prevent both 7, 8, 9
- Adjunctive therapy for breakthrough symptoms in GERD patients on PPIs 10, 11
Important Clinical Context
H2RAs are generally less effective than proton pump inhibitors (PPIs) for healing erosive esophagitis and providing symptom relief 1, 7. Standard doses of H2RAs suppress gastric acid by 37-68% over 24 hours, whereas PPIs provide more profound and prolonged acid suppression 12.
For NSAID-related gastric ulcer prevention, standard-dose H2RAs are inadequate 7. Double-dose H2RAs show some efficacy but are still inferior to PPIs 8, 9, 6. PPIs have proven superior to both ranitidine and misoprostol in preventing NSAID ulcer recurrence and controlling symptoms 7.
Side Effects and Limitations
Common Side Effects
The overall incidence of side effects is low (2-3%), including 3, 13:
- Headache
- Dizziness
- Constipation or diarrhea
- Mental confusion (especially in elderly or those with renal/hepatic impairment)
Specific Concerns
- Cimetidine has been specifically linked to increased risk of liver disease and gynecomastia, and these associations may extend to other H2RAs 1
- Tachyphylaxis develops fairly rapidly within 6 weeks of treatment, limiting long-term effectiveness 1, 10
- Drug interactions: Cimetidine and ranitidine inhibit cytochrome P-450 enzymes, potentially affecting metabolism of warfarin and theophylamine; famotidine does not have this interaction 13
Critical Limitation
The development of tachyphylaxis within 6 weeks is a major drawback that limits H2RAs for long-term acid suppression 1. This tolerance effect does not occur with PPIs, making them preferable for chronic conditions requiring sustained acid suppression.
Current Role in Practice
H2RAs have been largely supplanted by PPIs for most acid-related conditions 14, 5. Their current niche includes:
- On-demand therapy for mild, intermittent GERD symptoms 10, 11
- Nighttime breakthrough symptoms in patients already on PPIs (though limited by tachyphylaxis) 10
- Alternative to PPIs when de-prescribing or stepping down acid suppression 11
- Adjunctive use with antiplatelet therapy when PPIs are contraindicated, though they provide less GI protection than PPIs 12, 15
For patients requiring chronic acid suppression (erosive esophagitis, Barrett's esophagus, peptic stricture), PPIs remain the standard and H2RAs are inadequate 10.